Enzymatics T4 DNA Ligase（L6030HCL）超低价现货促销

EnzymaticsisaleADIngproducerofreagents,kits,andassaysthatenableourcustomersworldwidetotransformpatientdiagnosis,treatment,andlifescienceresearch.Ourbusinessunitsinclude:Reagents,SupplyChainSolutions,AppliedScience.

　　Ourpassionforquality,responsiveness,andflexibilityiscatalyzingthegenomichealthcarerevolution.

　　Enzymatics:CatalyzingtheGenomicsHealthcareRevolution

　　TheEnzymaticsstorystartsin2005whenStevePiconeandChrisBenoitwereproductionscientistsatamajormolecularBIOLOGyreagentscompany.Theyrealizedthattherewasanemergingneedinthemarketforlargequantitiesofultra-highpurityenzymesproducedconsistently,underarigorousqualitysystem,andofferedforsaleataverylowpricepoint.Thetechnologydrivingthesedemandswashigh-throughputDNAsequencing,whichutilizesenzymestotranslateaDNAsequenceintosearchabledata.Atthattime,sequencingwashardlyhigh-throughputasitcostover$10Mandtookmonthstodecodethesequenceofasinglehumangenome.SteveandChrisrecognizedthepotentialofDNAsequencingtorevolutionizemedicine,andconcludedthattheycoulduniquelymeetthisnewsetofrequirementsanddrivedownthecostofsequencing.TheystartedEnzymaticswiththeexpresspurposeofeliminatingthecostofsequencingasabarriertoadoptionintheclinicalsetting.Theplantoachievethiswastofocusonhighquality,well-controlledproduction,thedevelopmentofaclinically-alignedqualitysystem,treatingeverycustomerasapartner,andredefiningthewaybywhichreagentsarepriced.

　　SignificantReductioninCostofSequencing

　　AtEnzymatics,westrivetoconstantlychallengethestatusquo.IfwelookatarecentanalysisdonebytheNationalInstitutesofHealthontheaveragepricetosequenceahumangenomeovertime,itisclearthatin2007,thecostofsequencingbegantodropprecipitously.AlthoughthefactorsresponsIBLeforthisaccelerationtowardsaffordablesequencingarenumerous,Enzymaticswaspartofthattransformation.Infact,theheadofourscientificadvisoryboard,Dr.GeorgeChurch,athoughtleaderinsequencing,hasnotedthatEnzymaticshas,indeed,beenapowerfulcatalystinthedemocratizationofsequencing.

　　ANewErainHealthcare

　　Asaresultofthismassiveandcontinualreductioninthecostofsequencing,anentirelynewindustryhasemergedthatisleveragingthepowerofgeneticinformationtodiagnoseandtreathumandisease.Enzymaticshasbeenanenablingfactorinthebirthofthisnewsegmentofnucleicacid-baseddiagnostics,andweremainpassionatelycommittedtosupportingthecompanieswhosegenomictechnologieswillrevolutionizepersonalizedhealthcare.

　　CatalyzingtheGenomicHealthcareRevolution

　　In2006,whenEnzymaticsstarted,theconceptwastoenable“better,faster,cheaper”sequencingbyfocusingonthedesignandproductionoftheworld’sbestmolecularbiologyenzymes.Todayourproductsunderpinover80%ofthesequencingreactionsthatarerunaroundtheglobe,andwestilldobusinesswithnotonlyourveryfirstcustomer,butnearlyeveryothercompanywithwhomwe’vepartnered.